Clinical and regulatory intelligence for Follicular Lymphoma with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Relevant assets

Rituximab →

Tazemetostat →

Relevant companies

No related entities indexed yet.

Recent signals(2)

ClinicalJuly 2, 2026

Epizyme's Tazemetostat Shows Promise in Follicular Lymphoma Trial

Stage 1 of the trial assessing Tazemetostat in combination with Lenalidomide and Rituximab has been completed, focusing on safety and tolerability.

CompetitiveJuly 2, 2026

Phase III Trial Compares Rituximab and Mosunetuzumab in Low Tumor Burden Follicular Lymphoma

A phase III trial is underway to compare the effectiveness of rituximab and mosunetuzumab in treating low tumor burden follicular lymphoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Follicular Lymphoma →

Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.